The abstract is read at the publisher; the summary is JClub's.
Restricting Myelodysplastic Syndrome to <10% blasts (MDS-2022) in the Molecular International Prognostic Scoring System cohort increases median survival from 3.4 to 4.3 years.
- Why it matters: Survival gains reported over time may be biased if historical cohorts are reclassified, yet the effect of changing MDS/AML category definitions is often overlooked.
- What they did: The study compared survival between MDS-2016 (≤19% blasts) and MDS-2022 (<10% blasts) to simulate a cohort without an MDS/AML category.
- The result: Median survival and 5-year survival both shift upward with reclassification alone, from 3.4 to 4.3 years and from 39.0% to 43.6%, implying apparent improvements can be diagnostic artifacts.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.